Neurogene
NGNE
112 hedge funds and large institutions have $544M invested in Neurogene in 2026 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 38 increasing their positions, 31 reducing their positions, and 4 closing their positions.
709% more call options, than puts
Call options by funds: $3.79M | Put options by funds: $469K
450% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 4
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
59% more capital invested
Capital invested by funds: $342M → $544M (+$202M)
23% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 31
17% more funds holding
Funds holding: 96 → 112 (+16)
0.6% more ownership
Funds ownership: 108.96% → 109.56% (+0.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$5.62M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.91M |
| 3 |
MCM
Moore Capital Management
New York
|
+$3.9M |
| 4 |
CC
Casdin Capital
New York
|
+$3.44M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$3.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$5.02M |
| 2 |
Millennium Management
New York
|
-$4.46M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.07M |
| 4 |
Morgan Stanley
New York
|
-$2.57M |
| 5 |
State Street
Boston,
Massachusetts
|
-$2.44M |
NGNE Hedge Fund Activity: Q2 2026 in Review
112 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q2 2026, worth a combined $544M — up 59% from $342M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new NGNE positions and 4 closed out — a net gain of 18 holders — while 38 added to existing stakes and 31 trimmed.
The largest buyer was Franklin Resources, opening a new position worth an estimated $5.62M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $5.02M.
- 112 institutional investors held Neurogene (NGNE) as of Q2 2026, up from 96 in Q1 2026.
- Funds reported $544M of Neurogene stock for Q2 2026, up 59% quarter-over-quarter.
- 22 funds opened new Neurogene positions in Q2 2026 and 4 closed out, a net change of +18 holders.
- The largest Neurogene buyer in Q2 2026 was Franklin Resources, an estimated $5.62M added.
- The largest Neurogene seller in Q2 2026 was ArrowMark Colorado Holdings, an estimated $5.02M sold.
Based on aggregated 13F filings for Q2 2026.